- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Canopy Rivers Portfolio Company Gets Canadian License
Canopy Rivers announced its portfolio company Radicle Medical Marijuana obtained a production and sales license from Health Canada.
Canopy Rivers (TSXV:RIV) announced its portfolio company Radicle Medical Marijuana obtained a production and sales license from Health Canada.
As quoted in the press release:
First licensed for cultivation in early 2018, Radicle’s 140,000 square foot indoor facility located in Hamilton, ON is focused on small-batch cultivation of unique genetic strains using proprietary and sustainable growth methods. In August 2018, Radicle was one of the original twenty-six licensed cannabis producers selected in a highly competitive product call by the Ontario Cannabis Store for recreational sale online and one of two entities selected despite only having a licence to cultivate at the time. Radicle recently launched Gage Cannabis Co., a new premium brand in the craft cannabis segment.
“We are very proud to be part of the Radicle story,” said Daniel Pearlstein, EVP Strategy at Canopy Rivers. “This latest milestone marks a new and exciting chapter for Radicle and strengthens our confidence in their commitment to deliver premium, small-batch, handcrafted cannabis.”
Canopy Rivers first invested in Radicle in August 2017. The grant of the sales licence has triggered the conversion of Canopy Rivers’ convertible debenture into approximately 24 [percent] of the fully diluted issued and outstanding common shares of Radicle.
Click here to read the full press release.
Source: globenewswire.com
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.